CTOs on the Move

MDC Group

www.mdcomm.com

 
MDC Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mdcomm.com
  • 245 5th Ave
    New York, NY USA 10016
  • Phone: 212.679.3336

Executives

Name Title Contact Details

Similar Companies

The Rothman Institute

The Rothman Institute is affiliated with Hospitals consisting of state-of-the-art facilities befitting world-class orthopaedic centers. Everything, from clinical and surgical centers, a fully equipped imaging area (with the latest MRI equipment) and a physical therapy center, to a pain management area, an orthotic center and research laboratories, libraries and an educational center is all under one roof.

StoneRidge Treatment & Recovery

StoneRidge Treatment & Recovery is a leading addiction treatment center located in Prescott Valley. We specialize in providing world-class brain-focused mental health and addiction services. Our comprehensive approach includes addiction detox services,...

Healthcare Resource Network

Healthcare Resource Network is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.

Ebb Therapeutics

Sleep is essential and Ebb Therapeutics is working tirelessly to provide a clinically-proven, FDA-cleared device for the treatment of insomnia that is safe and effective for use every night -- without side effects.